

# Otto O Yang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8124558/publications.pdf>

Version: 2024-02-01

165  
papers

7,968  
citations

61984

43  
h-index

56724

83  
g-index

175  
all docs

175  
docs citations

175  
times ranked

12201  
citing authors

#	ARTICLE	IF	CITATIONS
1	Dominant CD8+ T Cell Nucleocapsid Targeting in SARS-CoV-2 Infection and Broad Spike Targeting From Vaccination. <i>Frontiers in Immunology</i> , 2022, 13, 835830.	4.8	19
2	Clinical Characteristics and Outcomes of Coronavirus Disease 2019 Patients Who Received Compassionate-Use Leronlimab. <i>Clinical Infectious Diseases</i> , 2021, 73, e4082-e4089.	5.8	23
3	Serological Responses to <i>Toxoplasma gondii</i> and Matrix Antigen 1 Predict the Risk of Subsequent Toxoplasmic Encephalitis in People Living With Human Immunodeficiency Virus (HIV). <i>Clinical Infectious Diseases</i> , 2021, 73, e2270-e2277.	5.8	5
4	Robust CAR-T memory formation and function via hematopoietic stem cell delivery. <i>PLoS Pathogens</i> , 2021, 17, e1009404.	4.7	19
5	Primary, Recall, and Decay Kinetics of SARS-CoV-2 Vaccine Antibody Responses. <i>ACS Nano</i> , 2021, 15, 11180-11191.	14.6	60
6	Longitudinal Analysis of the T-cell Receptor Repertoire in Graft-infiltrating Lymphocytes Following Hand Transplantation. <i>Transplantation</i> , 2021, 105, 1502-1509.	1.0	5
7	Longitudinal COVID-19 Surveillance and Characterization in the Workplace with Public Health and Diagnostic Endpoints. <i>MSphere</i> , 2021, 6, e0054221.	2.9	5
8	HLA-E-restricted HIV-1-specific CD8+ T cell responses in natural infection. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	12
9	Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 1365-1376.	10.7	119
10	The systemic inflammatory landscape of COVID-19 in pregnancy: Extensive serum proteomic profiling of mother-infant dyads with in utero SARS-CoV-2. <i>Cell Reports Medicine</i> , 2021, 2, 100453.	6.5	28
11	Humoral responses to SARS-CoV-2 mRNA vaccines: Role of past infection. <i>PLoS ONE</i> , 2021, 16, e0259703.	2.5	17
12	Previous Infection Combined with Vaccination Produces Neutralizing Antibodies with Potency against SARS-CoV-2 Variants. <i>MBio</i> , 2021, 12, e0265621.	4.1	14
13	A Novel HIV-1 Nef Mutation in a Primary Pediatric Isolate Impairs MHC-Class I Downregulation and Cytotoxicity. <i>AIDS Research and Human Retroviruses</i> , 2020, 36, 122-130.	1.1	0
14	Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19. <i>New England Journal of Medicine</i> , 2020, 383, 1085-1087.	27.0	986
15	Chimeric Antigen Receptors Targeting Human Cytomegalovirus. <i>Journal of Infectious Diseases</i> , 2020, 222, 853-862.	4.0	10
16	Human Vault Nanoparticle Targeted Delivery of Antiretroviral Drugs to Inhibit Human Immunodeficiency Virus Type 1 Infection. <i>Bioconjugate Chemistry</i> , 2019, 30, 2216-2227.	3.6	13
17	Nef-induced differential gene expression in primary CD4+ T cells following infection with HIV-1 isolates. <i>Virus Genes</i> , 2019, 55, 541-544.	1.6	3
18	Solution Structures of Engineered Vault Particles. <i>Structure</i> , 2018, 26, 619-626.e3.	3.3	14

#	ARTICLE	IF	CITATIONS
19	CD8+Cytotoxic T Lymphocyte Responses and Viral Epitope Escape in Acute HIV-1 Infection. <i>Viral Immunology</i> , 2018, 31, 525-536.	1.3	2
20	Highly Attenuated Infection With a Vpr-Deleted Molecular Clone of Human Immunodeficiency Virus-1. <i>Journal of Infectious Diseases</i> , 2018, 218, 1447-1452.	4.0	10
21	Cross-Reactivity against Multiple HIV-1 Epitopes Is Characteristic of HIV-1-Specific Cytotoxic T Lymphocyte Clones. <i>Journal of Virology</i> , 2018, 92, .	3.4	3
22	Changes in Plasma Levels of Oxidized Lipoproteins and Lipoprotein Subfractions with Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy and Associations with Common Carotid Artery Intima-Media Thickness: ACTG 5260s. <i>Antiviral Therapy</i> , 2017, 22, 113-126.	1.0	11
23	Demographics and natural history of HIV-1-infected spontaneous controllers of viremia. <i>Aids</i> , 2017, 31, 1091-1098.	2.2	38
24	Highly Human Immunodeficiency Virus-Exposed Seronegative Men Have Lower Mucosal Innate Immune Reactivity. <i>AIDS Research and Human Retroviruses</i> , 2017, 33, 788-795.	1.1	11
25	HIV-1 Epitope Variability Is Associated with T Cell Receptor Repertoire Instability and Breadth. <i>Journal of Virology</i> , 2017, 91, .	3.4	5
26	Human immune compartment comparisons: Optimization of proliferative assays for blood and gut T lymphocytes. <i>Journal of Immunological Methods</i> , 2017, 445, 77-87.	1.4	6
27	HLA-B*14:02-Restricted Env-Specific CD8 + T-Cell Activity Has Highly Potent Antiviral Efficacy Associated with Immune Control of HIV Infection. <i>Journal of Virology</i> , 2017, 91, .	3.4	14
28	Detection of Donor-Derived Microparticles in the Peripheral Blood of a Hand Transplant Recipient During Rejection. <i>Transplantation Direct</i> , 2017, 3, e131.	1.6	4
29	Effects of Mutations on Replicative Fitness and Major Histocompatibility Complex Class I Binding Affinity Are Among the Determinants Underlying Cytotoxic-T-Lymphocyte Escape of HIV-1 Gag Epitopes. <i>MBio</i> , 2017, 8, .	4.1	17
30	Distinct aging profiles of CD8+ T cells in blood versus gastrointestinal mucosal compartments. <i>PLoS ONE</i> , 2017, 12, e0182498.	2.5	41
31	HIV-1 epitopes presented by MHC class I types associated with superior immune containment of viremia have highly constrained fitness landscapes. <i>PLoS Pathogens</i> , 2017, 13, e1006541.	4.7	12
32	Clinical efficacy of gene-modified stem cells in adenosine deaminase-deficient immunodeficiency. <i>Journal of Clinical Investigation</i> , 2017, 127, 1689-1699.	8.2	70
33	Reimann's "Habitual Hyperthermia" Responding to Hormone Therapy. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw127.	0.9	2
34	Changes in Markers of T-Cell Senescence and Exhaustion With Atazanavir-, Raltegravir-, and Darunavir-Based Initial Antiviral Therapy: ACTG 5260s. <i>Journal of Infectious Diseases</i> , 2016, 214, 748-752.	4.0	9
35	Supranormal thymic output up to 2 decades after HIV-1 infection. <i>Aids</i> , 2016, 30, 701-711.	2.2	15
36	HIV-1-Specific Chimeric Antigen Receptors Based on Broadly Neutralizing Antibodies. <i>Journal of Virology</i> , 2016, 90, 6999-7006.	3.4	80

#	ARTICLE	IF	CITATIONS
37	Telmisartan increases vascular reparative capacity in older HIV-infected adults: a pilot study. <i>HIV Clinical Trials</i> , 2016, 17, 225-232.	2.0	5
38	Risks Associated With Lentiviral Vector Exposures and Prevention Strategies. <i>Journal of Occupational and Environmental Medicine</i> , 2016, 58, 1159-1166.	1.7	94
39	HSC Clonal Dynamics after T-Cell Depletion in a Nonhuman Primate Model of Lentiviral Gene Therapy. <i>Blood</i> , 2016, 128, 3702-3702.	1.4	0
40	T Lymphocyte Density and Distribution in Human Colorectal Mucosa, and Inefficiency of Current Cell Isolation Protocols. <i>PLoS ONE</i> , 2015, 10, e0122723.	2.5	33
41	Clonal CD8+ T Cell Persistence and Variable Gene Usage Bias in a Human Transplanted Hand. <i>PLoS ONE</i> , 2015, 10, e0136235.	2.5	6
42	Adenovirus vectors as HIV-1 vaccines. <i>Aids</i> , 2015, 29, 395-400.	2.2	9
43	Ectopic expression of anti-HIV-1 shRNAs protects CD8+ T cells modified with CD4 $\alpha$ CAR from HIV-1 infection and alleviates impairment of cell proliferation. <i>Biochemical and Biophysical Research Communications</i> , 2015, 463, 216-221.	2.1	16
44	HIV-specific Immunity Derived From Chimeric Antigen Receptor-engineered Stem Cells. <i>Molecular Therapy</i> , 2015, 23, 1358-1367.	8.2	111
45	Short Conserved Sequences of HIV-1 Are Highly Immunogenic and Shift Immunodominance. <i>Journal of Virology</i> , 2015, 89, 1195-1204.	3.4	27
46	Changes in Inflammation and Immune Activation With Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy: ACTG 5260s. <i>Clinical Infectious Diseases</i> , 2015, 61, 651-660.	5.8	103
47	Vaccine-Induced Linear Epitope-Specific Antibodies to Simian Immunodeficiency Virus SIVmac239 Envelope Are Distinct from Those Induced to the Human Immunodeficiency Virus Type 1 Envelope in Nonhuman Primates. <i>Journal of Virology</i> , 2015, 89, 8643-8650.	3.4	42
48	Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir. <i>Journal of Infectious Diseases</i> , 2015, 212, 1241-1249.	4.0	100
49	A High Throughput Biochemical Fluorometric Method for Measuring Lipid Peroxidation in HDL. <i>PLoS ONE</i> , 2014, 9, e111716.	2.5	24
50	Immunomodulation of Antiretroviral Drug-Suppressed Chronic HIV-1 Infection in an Oral Probiotic Double-Blind Placebo-Controlled Trial. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, 988-995.	1.1	56
51	Antigen-Presenting Cell Candidates for HIV-1 Transmission in Human Distal Colonic Mucosa Defined by CD207 Dendritic Cells and CD209 Macrophages. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, 241-249.	1.1	44
52	Ineffectual Targeting of HIV-1 Nef by Cytotoxic T Lymphocytes in Acute Infection Results in No Functional Impairment or Viremia Reduction. <i>Journal of Virology</i> , 2014, 88, 7881-7892.	3.4	4
53	Engineering the Human Thymic Microenvironment to Support Thymopoiesis In Vivo. <i>Stem Cells</i> , 2014, 32, 2386-2396.	3.2	50
54	Seminal Plasma HIV-1 RNA Concentration Is Strongly Associated with Altered Levels of Seminal Plasma Interferon- $\beta$ , Interleukin-17, and Interleukin-5. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, 1082-1088.	1.1	10

#	ARTICLE	IF	CITATIONS
55	Short Communication: HIV-1 Gag Genetic Variation in a Single Acutely Infected Participant Defined by High-Resolution Deep Sequencing. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, 806-811.	1.1	2
56	Hdl Redox Activity is Increased in HIV-Infected Men in Association with Macrophage Activation and Non-Calcified Coronary Atherosclerotic Plaque. <i>Antiviral Therapy</i> , 2014, 19, 805-811.	1.0	16
57	Differential Blood and Mucosal Immune Responses against an HIV-1 Vaccine Administered via Inguinal or Deltoid Injection. <i>PLoS ONE</i> , 2014, 9, e88621.	2.5	14
58	HIV-1 Quasispecies Delineation by Tag Linkage Deep Sequencing. <i>PLoS ONE</i> , 2014, 9, e97505.	2.5	25
59	Role of RANKL-RANK/osteoprotegerin pathway in cardiovascular and bone disease associated with HIV infection. <i>AIDS Reviews</i> , 2014, 16, 123-33.	1.0	8
60	War in the Body. , 2013, , .		2
61	Introduction of Exogenous T-cell Receptors Into Human Hematopoietic Progenitors Results in Exclusion of Endogenous T-cell Receptor Expression. <i>Molecular Therapy</i> , 2013, 21, 1055-1063.	8.2	36
62	Biomimetic enzyme nanocomplexes and their use as antidotes and preventive measures for alcohol intoxication. <i>Nature Nanotechnology</i> , 2013, 8, 187-192.	31.5	289
63	Combination of allele-specific detection techniques to quantify minority resistance variants in hepatitis B infection: A novel approach. <i>Journal of Virological Methods</i> , 2013, 190, 34-40.	2.1	4
64	Early Antigen Presentation of Protective HIV-1 KF11Gag and KK10Gag Epitopes from Incoming Viral Particles Facilitates Rapid Recognition of Infected Cells by Specific CD8 <sup>+</sup> T Cells. <i>Journal of Virology</i> , 2013, 87, 2628-2638.	3.4	40
65	HIV-1 Gag Cytotoxic T Lymphocyte Epitopes Vary in Presentation Kinetics Relative to HLA Class I Downregulation. <i>Journal of Virology</i> , 2013, 87, 8726-8734.	3.4	10
66	Perturbations of Circulating Levels of RANKL-Osteoprotegerin Axis in Relation to Lipids and Progression of Atherosclerosis in HIV-Infected and -Uninfected Adults: ACTG NWCS 332/A5078 Study. <i>AIDS Research and Human Retroviruses</i> , 2013, 29, 938-948.	1.1	13
67	Untrained young men have dysfunctional HDL compared with strength-trained men irrespective of body weight status. <i>Journal of Applied Physiology</i> , 2013, 115, 1043-1049.	2.5	13
68	A Stochastic Multi-Scale Model of HIV-1 Transmission for Decision-Making: Application to a MSM Population. <i>PLoS ONE</i> , 2013, 8, e70578.	2.5	6
69	HIV-1 Nef Sequence and Functional Compartmentalization in the Gut Is Not Due to Differential Cytotoxic T Lymphocyte Selective Pressure. <i>PLoS ONE</i> , 2013, 8, e75620.	2.5	10
70	Natural Killer T Cells in Advanced Melanoma Patients Treated with Tremelimumab. <i>PLoS ONE</i> , 2013, 8, e76829.	2.5	15
71	Understanding Escape. , 2013, , 81-96.		0
72	Retroviral Sex and Escape. , 2013, , 123-134.		0

#	ARTICLE	IF	CITATIONS
73	Engineering The Human Thymic Microenvironment To Support Thymopoiesis. <i>Blood</i> , 2013, 122, 3494-3494.	1.4	0
74	In Vivo Suppression of HIV by Antigen Specific T Cells Derived from Engineered Hematopoietic Stem Cells. <i>PLoS Pathogens</i> , 2012, 8, e1002649.	4.7	74
75	Early HLA-B*57-Restricted CD8 <sup>+</sup> T Lymphocyte Responses Predict HIV-1 Disease Progression. <i>Journal of Virology</i> , 2012, 86, 10505-10516.	3.4	38
76	Partial Escape of HIV-1 from Cytotoxic T Lymphocytes during Chronic Infection. <i>Journal of Virology</i> , 2012, 86, 7459-7463.	3.4	6
77	Immune Selection <i>In Vitro</i> Reveals Human Immunodeficiency Virus Type 1 Nef Sequence Motifs Important for Its Immune Evasion Function <i>In Vivo</i> . <i>Journal of Virology</i> , 2012, 86, 7126-7135.	3.4	23
78	Epitope targeting and viral inoculum are determinants of Nef-mediated immune evasion of HIV-1 from cytotoxic T lymphocytes. <i>Blood</i> , 2012, 120, 100-111.	1.4	21
79	Functional Analysis of HIV Type 1 Nef Gene Variants from Adolescent and Adult Survivors of Perinatal Infection. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 486-492.	1.1	9
80	Hydrodynamic stretching of single cells for large population mechanical phenotyping. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 7630-7635.	7.1	669
81	Combination therapy with daptomycin, linezolid, and rifampin as treatment option for MRSA meningitis and bacteremia. <i>Diagnostic Microbiology and Infectious Disease</i> , 2011, 71, 286-290.	1.8	46
82	Human leukocyte antigen class I haplotypes of human immunodeficiency virus-infected persons on Likoma Island, Malawi. <i>Human Immunology</i> , 2011, 72, 877-880.	2.4	3
83	Definition of the viral targets of protective HIV-1-specific T cell responses. <i>Journal of Translational Medicine</i> , 2011, 9, 208.	4.4	143
84	Increasing CTL Targeting of Conserved Sequences During Early HIV-1 Infection Is Correlated to Decreasing Viremia. <i>AIDS Research and Human Retroviruses</i> , 2011, 27, 391-398.	1.1	24
85	A biochemical fluorometric method for assessing the oxidative properties of HDL. <i>Journal of Lipid Research</i> , 2011, 52, 2341-2351.	4.2	70
86	Antiviral Activity of Human Immunodeficiency Virus Type 1 Gag-Specific Cytotoxic T Lymphocyte Targeting Is Not Necessarily Intrinsically Superior to Envelope Targeting. <i>Journal of Virology</i> , 2011, 85, 2474-2478.	3.4	8
87	Fine-tuning of T-cell receptor avidity to increase HIV epitope variant recognition by cytotoxic T lymphocytes. <i>Aids</i> , 2010, 24, 2619-2628.	2.2	28
88	A highly efficient short hairpin RNA potently down-regulates CCR5 expression in systemic lymphoid organs in the hu-BLT mouse model. <i>Blood</i> , 2010, 115, 1534-1544.	1.4	132
89	Good's syndrome remains a mystery after 55 years: A systematic review of the scientific evidence. <i>Clinical Immunology</i> , 2010, 135, 347-363.	3.2	209
90	Interleukin-2-unresponsive immune defects in good syndrome: Letter to the Editor. <i>Clinical Immunology</i> , 2010, 135, 496-498.	3.2	3

#	ARTICLE	IF	CITATIONS
91	Generation of robust CD8 <sup>+</sup> T cell responses against subdominant epitopes in conserved regions of HIV-1 by repertoire mining with mimotopes. <i>European Journal of Immunology</i> , 2010, 40, 1950-1962.	2.9	14
92	Protection against Bronchiolitis Obliterans Syndrome Is Associated with Allograft CCR7+CD45RA <sup>+</sup> T Regulatory Cells. <i>PLoS ONE</i> , 2010, 5, e11354.	2.5	32
93	Rapid T Cell Receptor Delineation Reveals Clonal Expansion Limitation of the Magnitude of the HIV-1-Specific CD8 <sup>+</sup> T Cell Response. <i>Journal of Immunology</i> , 2010, 185, 5935-5942.	0.8	21
94	Candidate Vaccine Sequences to Represent Intra- and Inter-Clade HIV-1 Variation. <i>PLoS ONE</i> , 2009, 4, e7388.	2.5	37
95	Engineering Antigen-Specific T Cells from Genetically Modified Human Hematopoietic Stem Cells in Immunodeficient Mice. <i>PLoS ONE</i> , 2009, 4, e8208.	2.5	51
96	Predicting the Impact of Blocking Human Immunodeficiency Virus Type 1 Nef In Vivo. <i>Journal of Virology</i> , 2009, 83, 2349-2356.	3.4	7
97	Disruption of an env tyrosine-dependent sorting signal does not affect susceptibility of HIV-1 to cytotoxic T lymphocytes. <i>Aids</i> , 2009, 23, 1449-1451.	2.2	3
98	Simultaneous assessment of CD4 and MHC-I downregulation by Nef primary isolates in the context of infection. <i>Journal of Virological Methods</i> , 2009, 161, 297-304.	2.1	11
99	Generation of T Lineage Cells from Human Embryonic Stem Cells in a Feeder Free System. <i>Stem Cells</i> , 2009, 27, 100-107.	3.2	39
100	Packaging limits and stability of HIV-1 sequences in a coxsackievirus B vector. <i>Vaccine</i> , 2009, 27, 3992-4000.	3.8	12
101	Assessing the Antiviral Activity of HIV-1-Specific Cytotoxic T Lymphocytes. <i>Methods in Molecular Biology</i> , 2009, 485, 407-415.	0.9	6
102	Retracing our STEP towards a successful CTL-based HIV-1 vaccine. <i>Vaccine</i> , 2008, 26, 3138-3141.	3.8	14
103	Differential immunogenicity of vaccinia and HIV-1 components of a human recombinant vaccine in mucosal and blood compartments. <i>Vaccine</i> , 2008, 26, 4617-4623.	3.8	11
104	Proliferation and Foxp3 Expression in Virus-Specific Memory CD8 <sup>+</sup> T Lymphocytes. <i>AIDS Research and Human Retroviruses</i> , 2008, 24, 1087-1095.	1.1	9
105	Telomerase-Based Pharmacologic Enhancement of Antiviral Function of Human CD8 <sup>+</sup> T Lymphocytes. <i>Journal of Immunology</i> , 2008, 181, 7400-7406.	0.8	156
106	Functional Adaptation of Nef to the Immune Milieu of HIV-1 Infection In Vivo. <i>Journal of Immunology</i> , 2008, 180, 4075-4081.	0.8	35
107	Primary Human Immunodeficiency Virus Type 1 (HIV-1) Infection during HIV-1 Gag Vaccination. <i>Journal of Virology</i> , 2008, 82, 2784-2791.	3.4	7
108	Cross-Clade Detection of HIV-1-Specific Cytotoxic T Lymphocytes Does Not Reflect Cross-Clade Antiviral Activity. <i>Journal of Infectious Diseases</i> , 2008, 197, 390-397.	4.0	45

#	ARTICLE	IF	CITATIONS
109	Aiming for successful vaccine-induced HIV-1-specific cytotoxic T lymphocytes. <i>Aids</i> , 2008, 22, 325-331.	2.2	15
110	Bronchoalveolar Immunologic Profile of Acute Human Lung Transplant Allograft Rejection. <i>Transplantation</i> , 2008, 85, 1056-1059.	1.0	52
111	Availability of a Diversely Avid CD8+ T Cell Repertoire Specific for the Subdominant HLA-A2-Restricted HIV-1 Gag p2419â€²27 Epitope. <i>Journal of Immunology</i> , 2007, 178, 7756-7766.	0.8	25
112	Epitope-Dependent Avidity Thresholds for Cytotoxic T-Lymphocyte Clearance of Virus-Infected Cells. <i>Journal of Virology</i> , 2007, 81, 4973-4980.	3.4	67
113	Pediatric HIV-1â€²Specific Cytotoxic T-Lymphocyte Responses Suggesting Ongoing Viral Replication Despite Combination Antiretroviral Therapy. <i>Pediatric Research</i> , 2007, 61, 692-697.	2.3	8
114	Delayed Reconstitution of CD4+ iNKT Cells after Effective HIV Type 1 Therapy. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 913-922.	1.1	23
115	Gag-Specific CD8+ T Lymphocytes Recognize Infected Cells before AIDS-Virus Integration and Viral Protein Expression. <i>Journal of Immunology</i> , 2007, 178, 2746-2754.	0.8	247
116	Paradoxical Effects of Two Theta-Defensins on HIV Type 1 Infection. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 508-514.	1.1	5
117	Exposure to Wild Primates among HIV-infected Persons. <i>Emerging Infectious Diseases</i> , 2007, 13, 1579-1582.	4.3	13
118	Autologous CD4/CD8 co-culture assay: A physiologically-relevant composite measure of CD8+ T lymphocyte function in HIV-infected persons. <i>Journal of Immunological Methods</i> , 2007, 327, 75-81.	1.4	22
119	HIV-1-Specific CTL Recognizing a Scarce Epitope Are Not Suppressed by HIV-1 Protease Inhibitors. <i>American Journal of Immunology</i> , 2007, 3, 1-3.	0.1	0
120	Transience of vaccine-induced HIV-1-specific CTL and definition of vaccine â€œresponseâ€². <i>Vaccine</i> , 2006, 24, 3426-3431.	3.8	6
121	Nef interference with HIV-1â€²specific CTL antiviral activity is epitope specific. <i>Blood</i> , 2006, 108, 3414-3419.	1.4	58
122	Interferon-Î³ decreases replication of primary R5 HIV-1 isolates in thymocytes. <i>Aids</i> , 2006, 20, 939-942.	2.2	5
123	A novel small reporter gene and HIV-1 fitness assay. <i>Journal of Virological Methods</i> , 2006, 133, 41-47.	2.1	25
124	Degeneracy and Repertoire of the Human HIV-1 Gag p1777â€²85CTL Response. <i>Journal of Immunology</i> , 2006, 176, 6690-6701.	0.8	27
125	HIV-1 Adapts to a Retrocyclin with Cationic Amino Acid Substitutions That Reduce Fusion Efficiency of gp41. <i>Journal of Immunology</i> , 2006, 176, 6900-6905.	0.8	45
126	Detection of HIV-1-specific CTL responses in Clade B infection with Clade C Peptides and not Clade B consensus peptides. <i>Journal of Immunological Methods</i> , 2005, 296, 1-10.	1.4	10



#	ARTICLE	IF	CITATIONS
127	Decreased perforin and granzyme B expression in senescent HIV-1-specific cytotoxic T lymphocytes. <i>Virology</i> , 2005, 332, 16-19.	2.4	59
128	Evasion of cytotoxic T lymphocytes is a functional constraint maintaining HIV-1 Nef expression. <i>European Journal of Immunology</i> , 2005, 35, 3221-3228.	2.9	18
129	Genetic and Stochastic Influences on the Interaction of Human Immunodeficiency Virus Type 1 and Cytotoxic T Lymphocytes in Identical Twins. <i>Journal of Virology</i> , 2005, 79, 15368-15375.	3.4	37
130	Human Immunodeficiency Virus Type 1 Clade B Superinfection: Evidence for Differential Immune Containment of Distinct Clade B Strains. <i>Journal of Virology</i> , 2005, 79, 860-868.	3.4	79
131	How Many Human Immunodeficiency Virus Type 1-Infected Target Cells Can a Cytotoxic T-Lymphocyte Kill?. <i>Journal of Virology</i> , 2005, 79, 13579-13586.	3.4	38
132	Parallel Human Immunodeficiency Virus Type 1-Specific CD8 + T-Lymphocyte Responses in Blood and Mucosa during Chronic Infection. <i>Journal of Virology</i> , 2005, 79, 4289-4297.	3.4	58
133	Clonal breadth of the HIV-1-specific T-cell receptor repertoire in vivo as determined by subtractive analysis. <i>Aids</i> , 2005, 19, 887-896.	2.2	9
134	Effects of HIV-1 infection on lymphocyte phenotypes in blood versus lymph nodes. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005, 39, 507-18.	2.1	10
135	Impacts of Epitope Expression Kinetics and Class I Downregulation on the Antiviral Activity of Human Immunodeficiency Virus Type 1-Specific Cytotoxic T Lymphocytes. <i>Journal of Virology</i> , 2004, 78, 561-567.	3.4	34
136	Beyond Help: Direct Effector Functions of Human Immunodeficiency Virus Type 1-Specific CD4 + T Cells. <i>Journal of Virology</i> , 2004, 78, 8844-8851.	3.4	89
137	Culturing of HIV-1-specific cytotoxic T lymphocytes with interleukin-7 and interleukin-15. <i>Virology</i> , 2004, 325, 175-180.	2.4	5
138	CTL ontogeny and viral escape: implications for HIV-1 vaccine design. <i>Trends in Immunology</i> , 2004, 25, 138-142.	6.8	24
139	Persistent alterations in the T-cell repertoires of HIV-1-infected and at-risk uninfected men. <i>Aids</i> , 2004, 18, 161-170.	2.2	23
140	Chimeric immune receptor T cells bypass class I requirements and recognize multiple cell types relevant in HIV-1 infection. <i>Virology</i> , 2003, 306, 371-375.	2.4	9
141	Half-genome human immunodeficiency virus type 1 constructs for rapid production of reporter viruses. <i>Journal of Virological Methods</i> , 2003, 110, 137-142.	2.1	27
142	Optimization of methods to assess human mucosal T-cell responses to HIV infection. <i>Journal of Immunological Methods</i> , 2003, 279, 17-31.	1.4	96
143	Antibacterial activity of peptides derived from envelope glycoproteins of HIV-1. <i>FEBS Letters</i> , 2003, 535, 195-199.	2.8	7
144	Will we be able to "spot" an effective HIV-1 vaccine?. <i>Trends in Immunology</i> , 2003, 24, 67-72.	6.8	69

#	ARTICLE	IF	CITATIONS
145	Determinants of HIV-1 Mutational Escape From Cytotoxic T Lymphocytes. <i>Journal of Experimental Medicine</i> , 2003, 197, 1365-1375.	8.5	121
146	Impacts of Avidity and Specificity on the Antiviral Efficiency of HIV-1-Specific CTL. <i>Journal of Immunology</i> , 2003, 171, 3718-3724.	0.8	86
147	The $\beta$ -Defensin, Retrocyclin, Inhibits HIV-1 Entry. <i>AIDS Research and Human Retroviruses</i> , 2003, 19, 875-881.	1.1	138
148	Broadly Increased Sensitivity to Cytotoxic T Lymphocytes Resulting from Nef Epitope Escape Mutations. <i>Journal of Immunology</i> , 2003, 171, 3999-4005.	0.8	21
149	Epitope Escape Mutation and Decay of Human Immunodeficiency Virus Type 1-Specific CTL Responses. <i>Journal of Immunology</i> , 2003, 171, 5372-5379.	0.8	68
150	Differential Impairment of Lytic and Cytokine Functions in Senescent Human Immunodeficiency Virus Type 1-Specific Cytotoxic T Lymphocytes. <i>Journal of Virology</i> , 2003, 77, 3077-3083.	3.4	80
151	Immunologic Profile of Highly Exposed Yet HIV Type 1-Seronegative Men. <i>AIDS Research and Human Retroviruses</i> , 2002, 18, 1051-1065.	1.1	33
152	TCR $\beta$ <sup>+</sup> and CD161 <sup>+</sup> Thymocytes Express HIV-1 in the SCID-hu Mouse, Potentially Contributing to Immune Dysfunction in HIV Infection. <i>Journal of Immunology</i> , 2002, 169, 5338-5346.	0.8	18
153	Retrocyclin: A primate peptide that protects cells from infection by T- and M-tropic strains of HIV-1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 1813-1818.	7.1	287
154	Nef-Mediated Resistance of Human Immunodeficiency Virus Type 1 to Antiviral Cytotoxic T Lymphocytes. <i>Journal of Virology</i> , 2002, 76, 1626-1631.	3.4	104
155	Monocyte Chemoattractant Protein-2 (CC Chemokine Ligand 8) Inhibits Replication of Human Immunodeficiency Virus Type 1 via CC Chemokine Receptor 5. <i>Journal of Infectious Diseases</i> , 2002, 185, 1174-1178.	4.0	28
156	CD1d on Myeloid Dendritic Cells Stimulates Cytokine Secretion from and Cytolytic Activity of V $\alpha$ 24 $\beta$ Q T Cells: A Feedback Mechanism for Immune Regulation. <i>Journal of Immunology</i> , 2000, 165, 3756-3762.	0.8	60
157	Inhibition of Human Immunodeficiency Virus Type 1 Replication in Primary CD4 <sup>+</sup> T Lymphocytes, Monocytes, and Dendritic Cells by Cytotoxic T Lymphocytes. <i>Journal of Virology</i> , 2000, 74, 6695-6699.	3.4	17
158	In Vitro Inhibition of HIV-1 by Met-Sdf-1 $\alpha$ Alone or in Combination with Antiretroviral Drugs. <i>Antiviral Therapy</i> , 2000, 5, 199-204.	1.0	7
159	Intrinsic Human Immunodeficiency Virus Type 1 Resistance of Hematopoietic Stem Cells Despite Coreceptor Expression. <i>Journal of Virology</i> , 1999, 73, 728-737.	3.4	99
160	Efficient Processing of the Immunodominant, HLA-A*0201-Restricted Human Immunodeficiency Virus Type 1 Cytotoxic T-Lymphocyte Epitope despite Multiple Variations in the Epitope Flanking Sequences. <i>Journal of Virology</i> , 1999, 73, 10191-10198.	3.4	42
161	Enhanced Inhibition of Human Immunodeficiency Virus Type 1 by Met-Stromal-Derived Factor 1 $\alpha$ Correlates with Down-Modulation of CXCR4. <i>Journal of Virology</i> , 1999, 73, 4582-4589.	3.4	57
162	$\beta$ -Chemokines are released from HIV-1-specific cytolytic T-cell granules complexed to proteoglycans. <i>Nature</i> , 1998, 391, 908-911.	27.8	297

#	ARTICLE	IF	CITATIONS
163	CD8+ Cells in Human Immunodeficiency Virus Type I Pathogenesis: Cytolytic and Noncytolytic Inhibition of Viral Replication. <i>Advances in Immunology</i> , 1997, 66, 273-311.	2.2	100
164	COVID-19 vaccine dosage in children, adolescents, and young adults “ is less more?. <i>Open Forum Infectious Diseases</i> , 0, , .	0.9	0
165	Reply to Viel. <i>Clinical Infectious Diseases</i> , 0, , .	5.8	0